In Q1'26, ABBV's total operating expenses reached $3.578B USD, comprising $0 in R&D expenses and $3.578B in SG&A expenses, reflecting a stable SG&A component amid the absence of reported R&D spending for the period. From Q2'23 to Q1'26, R&D expenses exhibited steady growth from $1.733B to a peak of $2.579B in Q4'25, with an anomalous spike to $6.774B in Q4'24 likely due to one-time factors, before dropping to no data in Q1'26; meanwhile, SG&A expenses fluctuated between $3.193B and $4.205B, showing overall stability with a slight upward trend to $3.578B in Q1'26, contributing to total operating expenses that trended higher over the 3-year span amid increasing investments in research and administrative functions.